ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Emmaus Life Sciences Announces Withdrawal of MAA to European Medicines Agency
September 23, 2019Emmaus Life Sciences announced the withdrawal of its marketing authorization application (MAA) to the European Medicines Agency (EMA) for Xyndari™ (glutamine) for the treatment of sickle cell disease. -
Emmaus Granted European Patent for L-glutamine to Treat Diverticulosis
September 04, 2019Emmaus Life Sciences has announced the allowance of patent application number 12860587.0, directed to the treatment of diverticulosis, by the European Patent Office. -
Emmaus Announces Initiation of its Diverticulosis Study
July 09, 2019Emmaus Life Sciences announced the screening of the first patient for the company's Pilot/Phase 1 study on the treatment of diverticulosis with pharmaceutical-grade L-glutamine (PGLG).
Pharma Sources Insight January 2025
